Sparks commentary - SynAct Pharma

Healthcare

Sparks - SynAct Pharma

More on this equity
Synact Pharma (STO: SYNACT) appoints Malin Wikstrand as interim CFO
Published by Jyoti Prakash, CFA

Synact Pharma has appointed Malin Wikstrand as interim CFO, following the planned departure of Björn Westberg (announced in September 2025). Ms Wikstrand has been with Synact since 2016 and most recently served as financial controller, bringing long-standing company knowledge and broad financial experience from listed companies. Management expects to appoint a permanent CFO in the coming months, coinciding with a key corporate inflection point marked by its forthcoming top-line data from the Phase IIb ADVANCE trial evaluating lead asset resomelagon in newly diagnosed rheumatoid arthritis.